CVS Health (CVS) option implied volatility increases, Amazon (AMZN) has agreed to acquire PillPack
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
CVS Health (CVS) PT Lowered to $84 at RBC Capital on Amazon Effect
June 29, 2018 7:10 AM EDTRBC Capital lowered its price target on CVS Health (NYSE: CVS) to $84.00 (from $91.00) while maintaining an Outperform rating to reflect Amazon's entrance into the pharmacy space.
"We acknowledge that Amazon has disrupted industries in the past, but believe that the stickiness of payer/ pharmacy... More
Buy CVS Health (CVS) and Express Scripts (ESRX) on Amazon/PillPack Deal Weakness - Mizuho
June 28, 2018 11:47 AM EDTMizuho analyst Ann Hynes said they would be buyers of CVS Health (NYSE: CVS) and Express Scripts (NASDAQ: ESRX) amid weakness related to Amazon's purchase of PillPack.
Hynes said the bark of the deal is likely worse than the bite, at lease initially. "Obviously from a multiple perspective, this announcement will weigh on valuation. From an earnings and cash flow perspective, that impact is less clear and our initial thoughts is market share gains will be limited, at least in the intermediate-term. We confirmed... More
